163
one could argue we’re still in denial given the Federal illegality and society perception. We think banking reform will usher in the migration as Wall Street adopts the space and packages financial products for sale. And then we have US decriminalization, UN reclassification and clinical trials to fuel the transition to panic, or FOMO.
So that’s on the horizon; and much like dot.com, after that thrust higher, Facebook and Friendster and MySpace, or the cannabis-equivalent of them, will figure out what they want to be when they grow up, or if they’re fortunate enough to age. Most of the 700-odd cannabis stocks will likely fail, just as most dot.com stocks did, but we believe the ones that succeed will create generational wealth. As an aside, we think people will be astounded by the ubiquity of the use-cases and end-products, most of which are non-euphoric, or how it will touch almost every industry. It’ll be fun to watch evolve.
Cheers. My own approach has been to focus on the importance of awareness and education as a key driver to investor success and I admit that is a broad statement because it encompasses everything from the Consolidation Curve to understanding the forces of supply and demand to staying on top of medical and scientific trials and regulatory changes and approvals.
How important is it for investors to source reliable relevant current information from reputable sources?
There are so many hucksters out there, just a huge credibility gap; so yes, just like anything in life, the source of your information will play a massive role in your ability to retain the correct information.
At CB1 Capital, we monitor catalysts across the State, Federal and international arenas, and follow the clinical trials – we follow the science – to help guide our bio-pharma investments. And we offer a free daily recap of our findings, so if anyone is interested please visit www.cb1cap.com.